NCT00267696View on ClinicalTrials.gov

Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

September 30, 2013

Study Completion Date

December 31, 2013

Conditions
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Interventions
DRUG

Bevacizumab

Bevacizumab(Avastin)=10mg/kg on day 1, day 15 of a 28 day cycle.

DRUG

Gemcitabine

A regimen consisting of gemcitabine 1000 mg/m2 will be administered on day 1 and day 15 of a 28 day cycle

DRUG

Carboplatin

Trial Locations (1)

43210

The Ohio State University & James Cancer Hospital, Columbus

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

Ohio State University Comprehensive Cancer Center

OTHER